4-(((methylsulfonyl)oxy)methyl)quinoline | 105590-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(((methylsulfonyl)oxy)methyl)quinoline
• 英文别名: 4-(methanesulfonyloxymethyl)quinoline；4-quinolinylmethyl methanesulfonate；quinolin-4-ylmethyl methanesulfonate
• CAS: 105590-02-1
• 化学式: C₁₁H₁₁NO₃S
• 分子量: 237.279
• InChiKey: RVJUILCHJOASSK-UHFFFAOYSA-N

物化性质

• 熔点：
  100-102 °C (decomp)
• 沸点：
  463.8±28.0 °C(Predicted)
• 密度：
  1.340±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(((methylsulfonyl)oxy)methyl)quinoline 生成 diethyl [(quinolin-4-yl)methyl]phosphonate
  参考文献：
  名称：

  HUTCHISON, ALAN J.;SHAW, KENNETH R.;SCHNEIDER, JOSEF A.

  摘要：

  DOI：
• 作为产物：
  描述：

  4-喹啉甲醛 在 sodium tetrahydroborate 、 三乙胺 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 2.5h， 生成 4-(((methylsulfonyl)oxy)methyl)quinoline
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Hapten‐Clicked Analogues of The Antigenic Peptide Melan‐A/MART‐1 _26(27L)‐35

  摘要：

  AbstractA click‐chemistry‐based approach was implemented to prepare peptidomimetics designed in silico and made from aromatic azides and a propargylated GIGI‐mimicking platform derived from the altered Melan‐A/MART‐126(27L)‐35 antigenic peptide ELAGIGILTV. The CuI‐catalyzed Huisgen cycloaddition was carried out on solid support to generate rapidly a first series of peptidomimetics, which were evaluated for their capacity to dock at the interface between the major histocompatibility complex class‐I (MHC‐I) human leucocyte antigen (HLA)‐A2 and T‐cell receptors (TCRs). Despite being a weak HLA‐A2 ligand, one of these 11 first synthetic compounds bearing a p‐nitrobenzyl‐triazole side chain was recognized by the receptor proteins of Melan‐A/MART‐1‐specific T‐cells. After modification of the N and C termini of this agonist, which was intended to enhance HLA‐A2 binding, one of the resulting seven additional compounds triggered significant T‐cell responses. Thus, these results highlight the capacity of naturally circulating human TCRs that are specific for the native Melan‐A/MART‐126‐35 peptide to cross‐react with peptidomimetics bearing organic motifs structurally different from the native central amino acids.

  DOI：

  10.1002/cmdc.202000038

文献信息

• Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof
  申请人：Ciba-Geigy Corporation

  公开号：US04906621A1

  公开（公告）日：1990-03-06

  The present invention is concerned with the phosphonic acids of formula I ##STR1## wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represents optionally substituted 2-carboxypyrrolidinyl, 2-carboxy-2,5-dihydropyrrolyl, 2-carboxy-1,2,3,6-tetrahydropyridinyl, 2-carboxy-1,2,5,6-tetrahydropyridinyl, 2-carboxypiperidinyl, 2-carboxytetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, 2-carboxy-2,3-dihydroindolyl or 2-carboxyperhydroindolyl as described herein, and in each of which the carboxy group may be functionalized in form of a pharmaceutically acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene provided that A does not represent a direct bond when Y represents 2-carboxypyrrolidinyl; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.

  本发明涉及式I的膦酸##STR1##其中膦酸基团的一个或两个酸性羟基可以被功能化为药学上可接受的单酯或二酯形式；其中Y代表可选择地取代的2-羧基吡咯烷基，2-羧基-2,5-二氢吡咯基，2-羧基-1,2,3,6-四氢吡啶基，2-羧基-1,2,5,6-四氢吡啶基，2-羧基哌啶基，2-羧基四氢喹啉基或2-羧基四氢喹啉基，如本文所述的2-羧基-2,3-二氢吲哚基或2-羧基四氢吲哚基，并且其中羧基可以被功能化为药学上可接受的酯或酰胺形式；A代表直接键，低烯基，低烷基亚甲基或低烷基亚烯基，其中A不代表直接键时，Y代表2-羧基吡咯烷基；及其药学上可接受的盐；其用于治疗哺乳动物的神经系统疾病，并作为N-甲基-D-天冬氨酸敏感的兴奋性氨基酸受体的拮抗剂。
• Certain 2-carboxypiperidyl-(alkylene or alkenylene)-phosphonic acids and
  申请人：Ciba-Geigy Corporation

  公开号：US04898854A1

  公开（公告）日：1990-02-06

  The present invention is concerned with the phosphonic acids of formula I ##STR1## wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represents optionally substituted 2-carboxypyrrolidinyl, 2-carboxy-2,5-dihydropyrrolyl, 2-carboxy-1,2,3,6-tetrahydropyridinyl, 2-carboxy-1,2,5,6-tetrahydropyridinyl, 2-carboxypiperidinyl, 2-carboxytetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, 2-carboxy-2,3-dihydroindolyl or 2-carboxyperhydroindolyl as described herein, and in each of which the carboxy group may be functionalized in form of a pharmaceutically acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene provided that A does not represent a direct bond when Y represents 2-carboxypyrrolidinyl; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.

  本发明涉及式I的膦酸##STR1##其中膦酸基团的一个或两个酸性羟基可能以药用可接受的单酯或二酯的形式进行官能化；其中Y表示可选择取代的2-羧基吡咯啉基、2-羧基-2,5-二氢吡咯基、2-羧基-1,2,3,6-四氢吡啶基、2-羧基-1,2,5,6-四氢吡啶基、2-羧基哌啶基、2-羧基四氢喹啉基或2-羧基四氢喹啉基、2-羧基-2,3-二氢吲哚基或2-羧基四氢吲哚基，如本文所述，在其中羧基可能以药用可接受的酯或酰胺形式进行官能化；A表示直链键、较低烯基、较低烷基亚甲基或较低烷基，前提是当Y表示2-羧基吡咯啉基时，A不表示直链键；及其药用可接受的盐；它们对于治疗哺乳动物的神经系统疾病以及作为N-甲基-D-天冬氨酸敏感的兴奋性氨基酸受体的拮抗剂是有用的。
• [EN] RENIN INHIBITORS<br/>[FR] INHIBITEURS DE RÉNINE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2011020193A1

  公开（公告）日：2011-02-24

  Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6-alkyl or C3-6-cycloalkyl, wherein said C1-6-alkyl or C3-6-cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.

  肾素抑制剂是螺环哌啶酰胺，其结构式为（I），以及其药物组合物，用于治疗心血管疾病和肾功能不全。其中n在每次出现时，独立地为0、1或2；R1为氢、C1-6-烷基或C3-6-环烷基，其中所述的C1-6-烷基或C3-6-环烷基基团可以独立地被1-3个卤素取代；A为（i）五元或六元饱和或不饱和杂环或碳环单环，或（ii）与另一个五元或六元饱和或不饱和杂环或碳环单环融合的五元或六元饱和或不饱和杂环或碳环环；V为键或-(C=O)-、-CH(OH)-、-CH2-或=CH-；U为键或-CH2-，或当V为=CH-时，U为-CH=；X为=CH-、=CF-、=C(OR3)-或-C=O-；Y为=CH-、=CF-、=N-，或当X为-C=O-时，Y为-N(R3)-。
• Certain phosphonic acid quinoline-2-carboxylic acids, esters or amides
  申请人：Ciba-Geigy Corporation

  公开号：US05217963A1

  公开（公告）日：1993-06-08

  The present invention is concerned with the phosphonic acids of formula I ##STR1## wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represents optionally substituted 2-carboxytetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, and in each of which the carboxy group may be functionalized in form of a pharmaceutically acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.

  本发明涉及式I的膦酸：##STR1## 其中膦酸基团的一个或两个酸性羟基可以以药学上可接受的单酯或双酯的形式进行官能化；其中Y代表可以选择取代的2-羧基四氢喹啉基或2-羧基戊二氢喹啉基，其中羧基可以以药学上可接受的酯或酰胺的形式进行官能化；A代表直接键，低烯基，低烷基亚甲基或低烷基；以及其药学上可接受的盐；它们对哺乳动物的神经系统疾病治疗和作为N-甲基-D-天门冬氨酸敏感性兴奋性氨基酸受体的拮抗剂是有用的。
• Certain phosphonic acids and derivatives useful for the treatment of
  申请人：Ciba-Geigy Corporation

  公开号：US05057506A1

  公开（公告）日：1991-10-15

  The present invention is concerned with the phosphonic acids of formula I ##STR1## wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represent optionally substituted 2-carboxypyrrolidinyl, 2-carboxy-2,5-dihydropyrrolyl, 2-carboxy-1,2,3,6-tetrahydropyridinyl, 2-carboxy-1,2,5,6-tetrahydropyridinyl, 2-carboxypiperidinyl, 2-carboxyetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, 2-carboxyl-2,3-dihydroindolyl or 2-carboxyperhydroindolyl as described herein, and in each of which the carboxy group may be functionalized in form of a pharmaceutical acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene provided that A does not represent a direct bond when Y represents 2-carboxypyrolidinyl; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.

  本发明涉及式I的膦酸，其中膦酸基团中的一个或两个酸性羟基可以以药学上可接受的单酯或二酯的形式进行官能化；其中Y代表可选择取代的2-羧基吡咯烷基，2-羧基-2,5-二氢吡咯基，2-羧基-1,2,3,6-四氢吡啶基，2-羧基-1,2,5,6-四氢吡啶基，2-羧基哌啶基，2-羧基四氢喹啉基或2-羧基过氢喹啉基，2-羧基-2,3-二氢吲哚基或2-羧基过氢吲哚基，如本文所述，在其中羧基可以以药学可接受的酯或酰胺的形式进行官能化；A代表直接键，较低的烯基，较低的烷基亚甲基或较低的烷基，但当Y代表2-羧基吡咯烷基时，A不代表直接键；以及其药学可接受的盐；它们对哺乳动物的神经系统疾病的治疗和作为N-甲基-D-天门冬氨酸敏感性兴奋性氨基酸受体的拮抗剂是有用的。